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Abstract
Introduction: The Relevant Outcome Scale for Alzheimer’s Disease (ROSA) is a new observer rating instrument
recently developed for routine medical practice. The validity and reliability of ROSA as well as sensitivity to changes
due to intervention were examined in an open-label, single-arm, multicenter clinical study in patients with
Alzheimer’s disease (AD).
Methods: The study enrolled 471 patients with a diagnosis of AD consistent with the criteria of the National
Institute of Neurological and Communicative Disease and Stroke/Alzheimer’s Disease and Related Disorders
Association or with the Diagnostic and Statistical Manual Disorders criteria for dementia of Alzheimer’s type.
Following assessments of the ROSA and other standard assessments (Alzheimer’s Disease Assessment Scale -
cognitive subscale, Severe Impairment Battery, Neuropsychiatric Inventory, and Disability Assessment for Dementia),
patients were treated with memantine for 12 weeks. Factor analysis of the baseline ROSA total scores was
performed based on the principal components method using the varimax orthogonal rotational procedure. The
psychometric analyses of the ROSA included internal consistency, test-retest reliability, inter-rater reliability,
construct validity, and responsiveness to changes over time.
Results: All items showed adequate factor loadings and were retained in the final ROSA as Factor 1 (all items
related to cognition, communication, function, quality of life and caregiver burden) and Factor 2 (all behavior
items). The ROSA demonstrated high internal consistency (Cronbach’s a = 0.93), test-retest reliability (intraclass
correlation coefficient = 0.93), and inter-rater reliability (intraclass correlation coefficient = 0.91). The correlation
coefficients between the ROSA and each of the validated scales ranged between 0.4 and 0.7, confirming the ROSA
construct validity. Nonsubstantial floor and ceiling effects were found in middle and late disease stages, whereas a
small ceiling effect was observed in the early stage. The ROSA responsiveness to change was high (responsiveness
index ≥0.8) for all severity stages.
Conclusions: The ROSA is a valid and reliable instrument to aid medical practitioners in sensitively assessing AD-
relevant symptoms over time in their clinical practice.
Introduction
The Relevant Outcome Scale for Alzheimer’sD i s e a s e
(ROSA) is a novel observer rating instrument recently
developed for daily clinical practice to allow physicians
and other medical practitioners with expertise in the
management of patients with dementia (for example,
psychologists, trained raters) to determine the severity
of relevant symptoms in Alzheimer’sd i s e a s e( A D )a n d
to document disease progression and therapy effects
over time. The need for an instrument such as the
ROSA was identified after a comprehensive literature
survey of existing AD rating scales widely used in clini-
cal practice, and after extensive discussions with medical
practitioners and caregiver experts [1]. The following
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scale: easy and quick administration; high reliability and
validity for AD; multidomain assessment of cognition,
activities of daily living, behavior, communication, qual-
ity of life, and caregiver burden; relevance for all AD
severity stages; suitability for long-term monitoring dis-
ease progression; and high sensitivity to treatment
effects [1]. Given these scale characteristics, the ROSA
was developed as a clinician assessment scale, including
16 items grouped into six dimensions (cognition, com-
munication, behavior, function, quality of life, and care-
giver burden). The items were selected by a standard
content validity approach based on literature data and
critical judgment of experts and caregivers on the most
practice-relevant assessment criteria for global clinical
evaluation of disease progression [1]. Altogether, the
ROSA uses 14 items for assessment of the actual clinical
status of a patient in terms of patient impairment and
behavior, and two items for evaluation of patient quality
of life and caregiver burden.
Three AD severity stages are designated in the ROSA
- early, middle and late. A number of scales and rating
systems are presently used for AD staging in clinical
practice and research [2-5]; however, the timing and
course of an individual disease progression can vary
greatly from one patient to another. Some broadly uti-
lized staging instruments, such as the Global Deteriora-
tion Scale (GDS) or the Clinical Dementia Rating Sum
of Boxes [2,3], may be used to determine the patient’s
disease stage prior to the ROSA administration. A con-
cise description of the three severity stages within the
ROSA is provided in the ROSA manual, which is a part
of the instrument. The stages are based on cognitive,
functional, and behavioral disease symptoms of a patient
and correspond to the widely used concepts of mild,
moderate and severe AD. Briefly, in the early stage, cog-
nitive deficits include, for example, word-finding and
name-finding difficulties, memory complaints for
recently learned information, or regularly misplacing
valuable objects. Patients may reveal troubles in plan-
ning, initiating, and performing in social settings; close
relatives, friends, or colleagues also start noticing cogni-
tive deficits in patients, which may not be apparent to
others. In the middle stage, forgetfulness for recent
events and autobiographical memories is increased, per-
formance in complex tasks is worse, and depressed
mood, withdrawal in a social situation, or other beha-
vioral changes may become noticeable. Patients demon-
strate difficulties in activities of daily living and
orientation. In the late stage, patients lose awareness of
recent events and of personal history, and the need for
help in activities of daily living is high. The ability to
respond to the environment as well as orientation in
space and time is severely impaired. Personality and
behavioral changes may also take place.
The rater has to appraise the patient’s disease stage
(early, middle, or late) before applying the ROSA evalua-
tion. A condition for the use of the ROSA is that the
rater - who can be the treating clinician or psychologist
in clinical settings, or also the nurse involved in medical
care - is familiar with the necessary background infor-
mation on the patient so that it can be incorporated as
part of the assessment. The staging must be based on
the comprehensive clinical impression about the patient.
The evaluation with the ROSA is made with the aid of
scenarios (events or situations). In the ROSA, everyday
scenarios are described for Items 1 to 14. The scenario
of an item remains the same for each severity stage, but
it is supplemented by three examples that describe the
capacities/behavior of the patient at each of the three
severity stages. Should a scenario of a particular ROSA
item not be applicable to an individual patient, the
ROSA provides the possibility of using alternative sce-
narios taking into account eventual cultural or gender
differences. A few examples of alternative scenarios are
given in the ROSA manual to illustrate this possibility.
In such cases, the rater is required to note the alterna-
tive scenarios used for the first assessment with the
ROSA and to apply these scenarios in any subsequent
ratings.
The ROSA is administered in interview form. The
interview partner is usually the primary caregiver. In the
early stage of disease, the patient alone can also be the
interview partner. During the interview, the rater asks
questions based on the scenarios defined in the ROSA
and makes an estimate of each item on a numerical
scale of 0 to 10. Higher scores indicate better patient
abilities/quality of life and less caregiver burden. The
final estimate is the ROSA total score given by the sum
of all 16 single-item scores (range 0 to 160). The range
of the total score is the same for all severity stages,
higher scores indicating less impairment and burden.
Complete instructions on the ROSA use in daily clinical
practice are provided with the ROSA manual. Both the
ROSA and the ROSA manual can be obtained upon
request from Merz Pharmaceuticals GmbH (Frankfurt
am Main, Germany) and will be free of charge for non-
commercial use.
In the present paper, we present the structure and
psychometric properties of the ROSA that were analyzed
in an open-label, single-arm, multicenter clinical trial in
patients with AD of all severity stages. The primary goal
of the study was to investigate the validity and reliability
of the newly developed instrument, the ROSA, as a
unique tool for assessment of AD progression in daily
clinical practice. The ability of the ROSA to measure
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siveness, was also tested based on the study results and
reported here.
Materials and methods
Study design and population
This open-label, multicenter, single-arm clinical study
was carried out in 32 primary care centers and 15 out-
patient clinics in Germany and Austria. The raters
were professionals familiar with the patient’sm e d i c a l
history and experienced in disease staging, progression,
and dementia care: treating clinicians and psycholo-
g i s t si nc l i n i c a ls e t t i n g sa sw e l la sn u r s e si n v o l v e di n
medical care. All raters underwent training for admin-
istration of the ROSA prior to the study start, partici-
pating in a workshop of 5 hours. Patients with a
diagnosis of AD consistent with the National Institute
of Neurological and Communicative Disease and
Stroke/Alzheimer’s Disease and Related Disorders
Association criteria or with the Diagnostic and Statisti-
cal Manual Disorders IV-TR criteria for dementia of
Alzheimer’s type were enrolled. Patients taking mem-
antine or any contraindicated medications (for exam-
ple, anticonvulsants, anti-Parkinson drugs, or other N-
methyl-D-aspartate receptor blockers) within the past
6 months were not eligible, but those on a stable
dosage of cholinesterase inhibitors for at least 2
months prior to study enrollment were eligible.
Patients with clinically significant, unstable central ner-
vous system or psychiatric disease other than AD,
including bipolar or unipolar depression, were also not
eligible. The majority of the patients had a knowledge-
able caregiver participating in the study. The study was
conducted in accordance with the principles of good
clinical practice and the World Medical Association
Declaration of Helsinki 1964 and its amendments and
subsequent clarifications. The relevant local ethics
committees approved the study and written informed
consent was obtained from patients or patients’ legally
acceptable representatives.
Out of 487 patients screened, 471 were eligible for
inclusion into the study. Following baseline assessments,
451 patients were treated with memantine for 12 weeks
(20 mg/day once daily). For statistical analysis, the
population was defined as: the safety evaluation set,
including all patients who took at least one dose of
study medication (451 patients, 95.8%); and the full ana-
lysis set (FAS), consisting of all patients of the safety
evaluation set for whom ROSA data were available from
screening to the study end (397 patients, 84.3%). Most
patients had a caregiver to accompany the patient to all
study visits and provide study-relevant information
about the patient.
Measures
Assessments with the ROSA were performed at screen-
ing and at baseline visits by the same rater for evalua-
tion of test-retest reliability. For initial AD staging, the
GDS was used at screening. At baseline, patients/care-
givers were asked to complete the Alzheimer’s Disease
Assessment Scale - cognitive subscale (ADAS-cog) [6],
the Severe Impairment Battery (SIB) [7], the Neuropsy-
chiatric Inventory (NPI) [8], the Disability Assessment
for Dementia (DAD) [9], and the Mini-Mental State
Estimation (MMSE) [5]. The ADAS-cog was adminis-
tered only to patients in the early and middle AD sever-
ity stages, and the SIB to those in the middle and late
AD severity stages. The scores obtained in Questions 1,
39, and 40 of the SIB did not enter analyses. The time
for scale administrations was recorded by the clinician.
Reliability analyses
To assess internal consistency of the ROSA, the Cron-
bach a coefficient [10] of the ROSA construct was cal-
culated from baseline data. As an indicator of the scale’s
reliability, the measurement error (Sε) was evaluated
according to the formula:
Sε = Sx

1 − Cronbach s · α,
where Sx is the standard deviation of the ROSA total
score at baseline. Inter-rater reliability was evaluated
based on videotaped ROSA administrations showing a
physician applying the ROSA to the caregiver of a
patient with early, middle, or late AD. Prior to the
assessment, raters were given clinical information on the
patients’ history, such as biographical facts, information
on disease manifestation, disease duration, treatment,
and psychometric tests (GDS and MMSE). The intra-
class correlation coefficient (ICC, Shrout-Fleiss reliability
single score) was computed based on assessments from
61 raters; that is, investigators from all 47 dementia care
centers who participated in the ROSA validation study.
Test-retest reliability was determined by two administra-
tion of the ROSA by the same rater within a period of
up to 10 days prior to any treatment. As quantitative
measures of the reliability, Bravais-Pearson and ICC
coefficients were used.
Validity analyses
To evaluate the construct validity of the ROSA, a factor
analysis based on the principal components method
using an orthogonal rotational procedure (Varimax) was
applied on baseline ROSA data. Initial factors were
selected on the basis of eigenvalues ≥1( K a i s e r - G u t t -
mann criterion). A threshold of ≥0.4 for single-item
loadings of each identified factor was predefined to
decide which items should remain in ROSA. Items with
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considered a part of the factor in which it has the high-
est loading. In addition, a scree test was applied as an
alternative criterion for the number of extracted factors.
The ROSA’s concurrent validity was tested by com-
p a r i s o nw i t ht h eA D A S - c o g ,S I B ,D A D ,a n dN P I ,a n d
was assessed by means of the Bravais-Pearson correla-
tion coefficient. A range of 0.4 to 0.7 for the correlation
coefficients between the ROSA and each of the validated
scales was predefined as acceptable to confirm the
ROSA construct validity.
Responsiveness analyses
The responsiveness of the ROSA to change after 12-
week treatment with memantine, 20 mg per day, was
determined by means of the responsiveness index (RI)
and Cohen’s d effect size [11,12]. The RI was calculated
according to the formula:
RI(x) =
¯ X+
Sx0
where ¯ X+ is the arithmetic mean of pre-post differ-
ences (week 12 to baseline) of the ROSA scores for all
patients with positive change in the total score (pre-post
difference > 0), and Sx0 is the standard deviation of pre-
post differences of the ROSA score for all patients with
negative or no change in the total score (pre-post differ-
ence ≤0). The analysis was performed using pooled and
severity-stage datasets. Only patients with nonmissing
values and retaining the severity stage throughout the
study were considered for evaluation. The Cohen’s d
value was calculated as the difference between mean
ROSA total scores at week 12 and baseline, divided by
the standard deviation of the pooled dataset. According
to Cohen [12], values of 0.20 to 0.49 indicate a small
effect size, values of 0.50 to 0.79 a moderate effect size,
and values ≥0.8 a large effect size.
All analyses were performed using SAS software, ver-
sion 9.1.3 (SAS, Inc., Cary, NC, USA).
Results
The ROSA validity and reliability were analyzed using
the safety evaluation set as well as the FAS baseline
study data, both resulting in the same factor structure of
the ROSA and similar psychometric characteristics. In
the present article, only results obtained from the FAS
analysis will be presented because, besides validity and
reliability of the ROSA, the FAS analysis also provides
an estimate of the ROSA responsiveness; that is, the
ability of the scale to detect changes over time due to a
treatment, which is an essential psychometric property
of all evaluative instruments.
Table 1 presents the baseline demographic character-
istics of the FAS population, overall and by disease
severity stages. All patient groups were comparable with
regard to age and gender proportions. Overall, the aver-
age age of the patients was 75.7 years and women con-
stituted 56.7% of the FAS population. The MMSE total
score distribution across the AD severity groups showed
a decrease in the mean MMSE score from the early
(23.3 ± 4.2) to the late (12.5 ± 5.5) disease stages. The
mean total scores of the other scales administered at
baseline (ADAS-cog, SIB, DAD, and NPI) also demon-
strated an increasing level of relevant impairment from
early to late disease severity stages (Table 1).
A requirement for using the ROSA in the clinical
study was that the clinician is familiar with the neces-
sary background information on the patient. All study
investigators were trained that the disease staging prior
to the ROSA administration should be most of all based
on the comprehensive clinical impression about the
patient. In addition, a structured global staging instru-
ment such as the GDS was used in the study to deter-
mine the severity stage of the patient for the use of the
ROSA. The GDS was applied at screening before the
ROSA administration in order to guide and standardize
the initial severity staging in the ROSA.
Construct validity
The Kaiser-Guttmann criterion as well as the scree test
produced two ROSA factors as follows: Factor 1, includ-
ing Items 1 to 6 and Items 12 to 16; and Factor 2,
including Items 7 to 11 (Table 2). All 16 ROSA items
showed adequate factor loadings (≥0.4) and therefore
Table 1 Demographic data at baseline
Early stage Middle
stage
Late stage Overall
Age (years) 74.1 (7.91) 76.3 (7.12) 78.3 (6.07) 75.7 (7.4)
Gender, female 84 (52.2%) 100 (57.1%) 41 (67.2%) 225
(56.7%)
White 161
(100.0%)
175 (100.0%) 61
(100.0%)
397 (100%)
Weight (kg) 74.0 (13.7) 72.0 (15.1) 67.6 (11.5) 72.1 (14.1)
Height (cm) 167.0 (8.9) 165.1 (9.1) 164.0 (8.1) 165.7 (8.89)
MMSE score 23.3 (4.2) 18.6 (5.2) 12.5 (5.5) 19.6 (6.1)
ADAS-cog
score
16.3 (6.4) 23.4 (8.4) - 20.0 (8.3)
SIB score
a - 79.1 (11.3) 62.6 (20.3) 74.7 (16.0)
DAD score 33.3 (6.8) 24.7 (9.4) 13.8 (8.3) 26.4 (10.6)
NPI score 9.7 (9.6) 14.1 (11.7) 22.2 (14.4) 13.9 (12.3)
Data presented as mean (standard deviation) or number (%) of patients (full
analysis set). ADAS-cog, Alzheimer’s Disease Assessment Scale - cognitive
subscale; DAD, Disability Assessment for Dementia; MMSE, Mini-Mental State
Estimation; NPI, Neuropsychiatric Inventory; SIB, Severe Impairment Battery.
aQuestions 1, 39, and 40 were omitted in this study.
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sing patient’s quality of life, showed a loading higher
than the defined threshold of 0.4 in both Factor 1 and
Factor 2 (a loading of 0.4063 in Factor 2). The resulting
Factor 1 comprises the AD-relevant symptom domains
of cognition, communication, and function/activity of
daily living, as well as patient quality of life and care-
giver burden. Factor 2 comprises all of the items rele-
vant for the assessment of behavior. Both factors
showed eigenvalues higher than 1, explaining 57% of the
total variance.
The Bravais-Pearson correlation coefficient was exam-
ined by comparing the ROSA baseline data with baseline
d a t af o rt h eA D A S - c o g ,S I B ,N P I ,a n dD A D( T a b l e3 ) .
The ROSA/ADAS-cog correlation was assessed for early
and middle disease stages only, while the ROSA/SIB
correlation was assessed for middle and late disease
stages. The values of the correlation coefficients varied
within the predefined range for all scales, confirming an
adequate correlation between the ROSA and each of the
other scales, and thus supporting the construct validity
of the ROSA.
Internal consistency
The resulting value of Cronbach’s a was 0.9279, indicat-
ing high internal consistency of the ROSA. A measure-
ment error of 7.66 points was calculated on the basis of
the standard deviation and Cronbach’s a as an indicator
of the scale’s reliability.
Inter-rater reliability
Data were obtained from independent assessments by 61
raters of three videotaped ROSA administrations, one
for each AD severity stage. Each rater provided assess-
ments of at least two videos, thus resulting in 122
assessments (early stage, 42 assessments; middle stage,
40 assessments; late stage, 40 assessments) used for ana-
lysis. Given that values of the ICC coefficient ≥0.8 indi-
cate a high intra-class correlation, the resulting
coefficient of 0.9056 demonstrates a high inter-rater
reliability for the scale.
Test-retest reliability
Figure 1 shows the distribution of the ROSA total scores
at screening versus baseline. Only patients with non-
missing values for both assessments were used for the
test-retest reliability analysis (382 patients of the FAS).
The time between the initial ROSA administration and
the ROSA retest was 6.6 ± 1.4 days (range of 1 to 10
days between screening and baseline visits). During this
period the patients were not treated with memantine.
Table 2 Factor analysis of the ROSA (baseline data, FAS)
ROSA item Symptom domain Factor Loading
1 The patient is able to remember events from a long time ago. Cognition Factor 1 0.6857
2 The patient is able to remember events of the recent past. Cognition 0.7448
3 The patient is able to plan and carry out complex procedures. Cognition 0.8526
4 The patient is able to make himself understood. Communication 0.7138
5 The patient is able to communicate. Communication 0.7966
6 The patient shows social competence. Communication 0.7289
12 The patient is competent at everyday tasks. Function/ADL 0.7791
13 The patient is attentive, shows interest in his surroundings. Function/ADL 0.7284
14 The patient is independent. Function/ADL 0.7849
15 The patient’s quality of life is (very good/very poor). Quality of life 0.4509
16 The burden for the caregiver is (very small/very large). Caregiver burden 0.6183
7 The patient behaves aggressively. Behavior Factor 2 0.7309
8 The patient is restless. Behavior 0.6248
9 The patient shows behavioral changes due to delusions. Behavior 0.7397
10 The patient is insecure. Behavior 0.5014
11 The patient’s behavior is cooperative. Behavior 0.6243
ADL, activity of daily living.
Table 3 Correlation of ROSA total scores with ADAS-cog,
SIB, NPI, and DAD scores
n Bravais-Pearson
coefficient
ADAS-cog 332 -0.4724
Severe Impairment Battery (SIB) 227 0.5000
Neuropsychiatric Inventory (NPI) 391 -0.5383
Disability Assessment for Dementia
(DAD)
384 0.7060
ADAS-cog, Alzheimer’s Disease Assessment Scale - cognitive subscale; n, total
number of patients (full analysis set); ROSA, Relevant Outcome Scale for
Alzheimer’s Disease. Missing item value imputation was applied for the ROSA,
SIB, ADAS-cog, and NPI. Completely missing values for a scale were not
replaced. Evaluations included only patients with available data for both
correlated scales.
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the missing influence of treatment, no systematic
changes or learning effects were expected to occur. The
correlation estimated by both the Bravais-Pearson coeffi-
cient and the ICC (0.9309 and 0.9301, respectively) were
higher than 0.7, indicating an excellent test-retest repro-
ducibility for the ROSA.
Responsiveness
To investigate the extent to which the ROSA could
measure relevant changes due to a treatment in patients
with early, middle, and late AD, the responsiveness of
the ROSA to change was assessed comparing baseline
ROSA data with the ROSA total scores after 12-week
treatment with memantine. The RI values determined
by disease stage were 0.81 for early stage, 1.54 for mid-
dle stage, and 1.70 for late stage. For the overall study
population, the RI was 1.25. Based on the defined ranges
according to Cohen [11], RI values ≥0.8 are considered
to demonstrate a large sensitivity of ROSA to treatment
effects. The ROSA therefore appeared to be sensitive to
measure relevant changes due to treatment in all study
populations (overall and severity-stage groups). The
Cohen’s d value was additionally estimated to appraise
the magnitude of the treatment effect measured with
the ROSA at study end. The results indicated a relatively
small effect size of memantine in patients in middle
stages (Cohen’s d = 0.2104) and late stages (Cohen’s d =
0.2232). In early AD, the effect size of memantine based
on Cohen’s d value (0.0340) was negligible.
Floor and ceiling effects
Possible floor and ceiling effects for each disease stage
were analyzed based on the ROSA total score distribu-
tion at baseline (Figure 2). The results demonstrated
that less than 5% of the patients in middle and late
stages had scores close to the minimum and maximum
ROSA total score, indicating no substantial floor/ceiling
effects for this population. In the early stage, 9.3%
patients had ROSA scores higher than 150, pointing to
a small ceiling effect in early AD.
Administration time
Table 4 provides an overview of the time needed for
completion of ROSA and the other widely used and
validated scales applied in the study. For all scales, the
time for administration at baseline and at week 12
remained constant by severity stage and overall (Table
4). The mean value for ROSA completion ranged from
13 to 15 minutes for all stages. For comparison, the
assessment of cognitive impairment with ADAS-cog or
S I Bs c a l e st o o ka b o u t2 5m i n u t e s ,w h e r e a s1 3t o1 8
minutes were needed for NPI completion, and 10 to 12
minutes for the DAD.
ICC = 0.93 
Figure 1 Test-retest reliability. Correlation between the Relevant Outcome Scale for Alzheimer’s Disease (ROSA) total scores at screening and
baseline. ICC, intraclass correlation coefficient.
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Cognitive decline is the cardinal symptom in AD; how-
ever, noncognitive symptoms as well as patient quality
of life and caregiver burden are also clinically relevant
targets for treatment of AD [13]. Presumably, a set of
rating scales would be necessary for use in daily medical
practice, as in clinical trials of pharmacological and non-
pharmacological interventions, to assess multiple AD-
relevant domains. Assessment is therefore not only time
consuming but current scales are not always applicable
to all dementia stages and fail to measure therapy effects
reliably [1]. A need for more sensitive instruments to
detect AD symptom progression over time has been
acknowledged [14,15].
The ROSA is a novel and unique multidomain assess-
ment scale in AD, which has been designed for the need
of daily clinical practice to assess disease progression
over time and to measure dementia treatment effects. In
the present article, we report the ROSA factorial struc-
ture based on clinical study data and discuss the psycho-
metric characteristics of the scale, demonstrating that
the ROSA is a valid, reliable and time-efficient observer-
rating instrument to aid medical practitioners in sensi-
tively assessing changes in AD symptoms over time.
The ROSA items cover a broad spectrum of AD
symptoms, including cognitive impairment (Items 1 to
3), communication and social interaction abilities (Items
4 to 6), behavioral symptoms (Items 7 to 11), and symp-
toms relevant to activities of daily living (Items 12 to
14). Items 15 and 16 provide an overall evaluation of
the patient’s quality of life and the caregiver’sb u r d e n ,
respectively. As demonstrated by the factor analysis, all
items initially included in the ROSA were retained in
the final ROSA clustered into two factors. The item
assessing patient’s quality of life (Item 15) showed the
lowest loading within Factor 1, which indicates a rather
weak relationship with the items comprising cognitive
and functional AD symptoms in the ROSA. On the
other hand, Item 15 showed a factor loading higher
than the defined threshold of 0.4 also within Factor 2,
Figure 2 Distribution of ROSA total scores at baseline in early, middle, and late disease stages. ROSA, Relevant Outcome Scale for
Alzheimer’s Disease.
Table 4 Time for administration of the ROSA and four
other scales
Administration Time (minutes)
Early stage Middle stage Late stage Overall
ROSA BL 13.6 (7.27) 15.5 (6.72) 14.4 (5.50) 14.5 (6.82)
W12 13.2 (5.48) 15.3 (6.54) 14.3 (4.79) 14.3 (5.93)
ADAS-cog BL 24.7 (7.39) 25.2 (7.51) - 25.2 (7.51)
W12 22.7 (7.45) 25.7 (8.06) - 24.3 (7.89)
SIB BL - 24.8 (9.08) 29.0 (10.21) 26.3 (9.89)
W12 - 24.5 (10.20) 26.4 (11.02) 25.4 (10.58)
NPI BL 14.3 (6.60) 15.9 (11.87) 18.2 (7.81) 15.6 (9.54)
W12 13.7 (7.20) 13.5 (6.46) 17.0 (8.40) 14.1 (7.19)
DAD BL 10.8 (6.20) 11.5 (5.28) 12.4 (5.89) 11.4 (5.77)
W12 9.9 (4.66) 11.3 (4.84) 11.6 (6.00) 10.8 (5.00)
Data presented as mean (standard deviation). ADAS-cog, Alzheimer’s Disease
Assessment Scale - cognitive subscale; BL, baseline; DAD, Disability
Assessment for Dementia; NPI, Neuropsychiatric Inventory; ROSA, Relevant
Outcome Scale for Alzheimer’s Disease; SIB, Severe Impairment Battery; W12,
week 12 after baseline.
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tionship with all behavior items within the ROSA. This
confirms the complexity of a patient’s quality of life rat-
ing and the influence of a number of factors on the
quality of life, including cognitive dysfunction, functional
disabilities, and neuropsychiatric symptoms, as recently
shown in a longitudinal study investigating the change
in proxy-rated quality of life in a large cohort of home-
living patients with AD [16]. The authors clearly
demonstrated that measures of quality of life seem to
comprise different functions than typical clinical vari-
ables such as cognitive and noncognitive dysfunction
and activity of daily living [16]. It is also interesting that
Item 13, describing the interest of the patient for his/
her surroundings, was included in the ROSA factor
comprising cognitive and functional/activity of daily liv-
ing items (Factor 1). Given that this symptom is usually
considered a core feature of apathy, its non-inclusion in
the ROSA behavioral factor allows it to be focused only
on the most disruptive symptoms.
High internal consistency and test-retest reliability of
the final ROSA were shown, pointing to a high reprodu-
cibility of the ROSA results. The content validity ana-
lyses demonstrated a good correlation between the
ROSA and each of the validated scales (ADAS-cog, SIB,
N P I ,a n dD A D )u s e da ss t a n d a r dm e a s u r e sf o rt h e
assessment of AD-relevant symptoms evaluated with the
ROSA. In the current study, the ROSA was always
applied prior to any other scale used in order to prevent
a possible influence on the ROSA by the other scales. A
putative limitation of the inter-rater reliability analysis
applied in this study was that ROSA assessment was
restricted to assessing the patient on video and to hav-
ing clinical information on the patient only available in
a written report. The results, however, showed good
inter-rater reliability for the ROSA. A more direct
approach for assessing inter-rater reliability required
personal interviews by 61 raters in Germany and Aus-
tria, which was not feasible.
The ROSA responsiveness - that is, the ability of the
ROSA to detect changes over time due to an interven-
tion - was tested by two widely used criteria: the RI
and Cohen’s d coefficient. The RI provided an esti-
mate of the ability of the ROSA to discriminate
between patients who have changed due to treatment
and those who have not benefited by the treatment. In
turn, Cohen’s d coefficient, which provides an estimate
of the effect size due to an intervention, was analyzed
to demonstrate the ability of the ROSA to detect any
change over time due to memantine treatment. Given
the differences in the responsiveness statistics of these
two parameters, it is not surprising that the values of
RI and Cohen’s d differ greatly. One could expect that
the RI values are higher than Cohen’s d values
because the RI numerator increases with exclusion of
change scores from nonimproved patients, and the
respective denominator becomes smaller with the
inclusion of the standard deviation of change only for
stable patients.
Altogether, the results indicate that the ROSA can
sensitively measure relevant changes in all disease sever-
ity stages (RI ≥0.8 in all stages) and can reliably analyze
the effect size of drug treatments. The latter was sup-
ported by the data for the ROSA estimate of the effect
size due to treatment with memantine, which was
s h o w nt ob ew i t h i nt h ek n o w nr a n g eo ft h em e m a n t i n e
efficacy in moderate and severe AD stages [17]. Subse-
quent clinical experience with the ROSA, as well as its
further use in clinical studies, would be necessary to
permit an accurate assessment of the change in the total
score that constitutes a clinically important difference,
and thus to enable more accurate assessment of the
ROSA responsiveness.
All clinicians taking part in the study were experi-
enced professionals in AD diagnosis and treatment.
Prior to initiating the study, all raters (physicians, psy-
chologists and nurses) were trained in the application of
the ROSA and the other AD scales.
With the ROSA training, the raters were instructed
how to estimate a patient’s disease severity prior to the
ROSA administration and how to use the relevant
examples of the scenarios within the ROSA. The raters
were informed that the initial staging is an essential pre-
requisite for the ROSA administration; it establishes the
assessment framework in the ROSA - that is, which
example of a scenario (early, middle, or late) should be
used for the assessment - and it ensures that, when
patients’ clinical symptoms are reassessed over time, any
changes in the severity stage could be detected by the
rater prior to the reassessment with the ROSA. Also,
raters were instructed to be careful when applying mod-
ified scenarios; that is, to document any change of an
item scenario and use the modified scenario again at the
ROSA follow-up assessment. A video example of the
ROSA administration was shown to demonstrate the
use of the scenarios within the ROSA and the possibility
to adjust an item scenario to the individual patient
when needed.
For 95% of the study patients, the same clinician per-
formed the assessments with the ROSA. The ROSA was
scored on the basis of information obtained from the
clinician interview and information available on the
patient’s medical history, clinical data, and previous
encounters of the clinician. The interview partner was
in most cases the primary caregiver who regularly sees
the patient, thus being able to answer the questions on
the basis of personal interaction with the patient during
the preceding week.
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substantial advantage of the ROSA in daily clinical prac-
tice. One should, however, consider that the ratings are
done for each stage using the same scoring range, while
the scenarios used for each disease stage represent
increasing levels of impairment. The ROSA total scores
can thus be directly compared only within a patient or
between patient groups of one and the same disease
severity stage. This is a certain limitation in using the
ROSA assessment in clinical trials for comparison of
patient groups with different disease severity stages.
Patients who change their severity stage over time may
have to be excluded from statistical analyses in clinical
trials; however, the individual results of the ROSA sur-
vey can still be compared relative to one another. Any
change in the severity stage of a patient could be used
as a global value of the AD progression and effects of
an intervention. Besides, the same scoring range for all
d i s e a s es t a g e sd o e sn o tl i m i tt h eu s eo ft h eR O S Ai n
routine medical practice where a single patient is
assessed and comparison between patients is not
needed. If a change in the severity stage of a patient
occurs since the last assessment with the ROSA, the
clinician can perform the new assessment in the same
way, using the same scenario for each item but with the
new examples provided for the respective new severity
stage. In such cases, the ROSA total score could not be
used for a direct comparison between the new and the
last assessments of the patient but the change in the
severity stage itself is a global estimate for the progres-
sion of the patient disease over the past time.
Altogether, the study results reported here demon-
strated that AD-relevant symptoms and their severity
can be reliably assessed with the ROSA in patients at all
disease severity stages. In addition to the ROSA total
score, a graphical presentation of the ROSA single-item
scores could easily be displayed on the ROSA sheet by
connecting the ticked fields on the numerical scale.
Given the possibility to use the same ROSA sheet for
following assessments of a single patient, clinicians
could directly compare two or more repeat evaluations
based on the graphical display of the single-item scores
as well. The ROSA may thus contribute to identifying
particular symptoms assessed with single ROSA items
that necessitate treatment and counseling. The item-spe-
cific ratings may have the advantage that, despite wor-
sening in the ROSA total score, item scores may
indicate the AD-relevant domains within the ROSA
responsible for the worsening and also the domains that
remain unchanged or even improve. This may be of par-
ticular benefit for studies on pharmacological and non-
pharmacological interventions where effects on specific
domains are expected to occur. The use of the ROSA
item scores in clinical practice and research, however,
needs to be appropriately validated in the future.
Conclusions
In summary, the ROSA is a valid, reliable, and sensitive
instrument for evaluating the severity of AD symptoms
in daily clinical practice over time. In general, the physi-
cians, psychologists, and nurses taking part as raters in
this study have commented that the ROSA is easy to
apply and useful in daily clinical practice. Nevertheless,
specific training is required for all users prior to admin-
istering the ROSA for the first time. For trained raters,
the administration of the ROSA takes about 15 minutes,
which is much less than the time a clinician would need
for administrating a set of domain-specific AD scales
covering all the domains efficiently covered by the
ROSA. While the sensitivity shown to change due to
treatment confirms the utility of the ROSA for assessing
short-term longitudinal change assessments, the broad
severity range and wide range of relevant items covered
by the ROSA are likely to be of great advantage for
assessing change in long-term clinical trials and for
assessing long-term longitudinal change.
Abbreviations
AD: Alzheimer’s disease; ADAS-Cog: Alzheimer’s Disease Assessment Scale -
cognitive subscale; DAD: Disability Assessment for Dementia; FAS: full
analysis set; GDS: Global Deterioration Scale; ICC: intraclass correlation
coefficient; MMSE: Mini-Mental State Examination; NPI: Neuropsychiatric
Inventory; RI: responsiveness index; ROSA: Relevant Outcome Scale for
Alzheimer’s Disease; SIB: Severe Impairment Battery.
Acknowledgements
Merz Pharmaceuticals GmbH, Germany, provided all financial and material
support for development of the trial design, implementation, and acquisition,
analysis and interpretation of data. The authors gratefully acknowledge, from
Pierrel Research Europe GmbH, Germany, Waldemar Braun who provided
expert advice and methodology for scale development, Melanie Buess who
provided statistical support, and Ivanka Yaneva-Hoffmann PhD who provided
editorial and medical writing support. The authors are indebted to all trial
investigators for their contribution to data acquisition.
Author details
1Old Age Psychiatry and Cognitive Neuropsychiatry, University Hospital Carl
Gustav Carus, University of Technology, Fetscherstraße 74, Dresden 01307,
Germany.
2DZNE, German Center for Neurodegenerative Diseases, Dresden,
Germany.
3Alzheimer’s Disease Center, New York University Langone Medical
Center, 550 First Avenue, New York, NY 10016, USA.
4Clinic of Geriatric
Psychiatry and Psychotherapy, Alexian Krefeld GmbH, Diessemer Bruch 81,
Krefeld 47805, Germany.
5University of Düsseldorf, Universitätsstraße 1, 40225
Düsseldorf, Germany.
6Memory Center EA CoBTek, Université de Nice Sophia
Antipolis, Hôpital de Cimiez, 4 av Victoria 06000, Nice, France.
7Karolinska
Institutet Alzheimer Disease Research Center, Novum 5th Floor, SE-141 86
Stockholm, Sweden.
8Alzheimer’s Disease Research Unit, McGill Centre for
Studies in Aging, 6825 LaSalle Boulevard, Verdun, Quebec H4H 1R3, Canada.
9Merz Pharmaceuticals GmbH, Eckenheimer Landstraße 100, Frankfurt 60318,
Germany.
10AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne,
Switzerland.
Authors’ contributions
All authors contributed to the ROSA development and to designing of the
clinical trial aiming at the ROSA validation. VAH was the coordination
Holthoff et al. Alzheimer’s Research & Therapy 2011, 3:27
http://alzres.com/content/3/5/27
Page 9 of 10investigator of the clinical trial and provided critical remarks on the
manuscript. FT developed the first draft of this article based on extensive
discussions with all other authors. KS contributed to planning and execution
of the statistical analyses. SF, RI, PR, BW, and SG provided critical remarks on
the manuscript. All authors read and approved the final manuscript.
Competing interests
In the past 5 years, VAH, SF, RI, PR, BW, and SG were members of an
Advisory Board for Alzheimer’s disease coordinated by Pierrel Research
Europe (Essen, Germany), for which they received honorarium from Merz
Pharmaceuticals (Frankfurt, Germany). KS is an employee of Merz
Pharmaceuticals and receives a fixed salary. At the time of the study, FT was
an employee of Merz Pharmaceuticals and received a fixed salary. RI, PR, and
BW are also members of the Advisory Board at Lundbeck, in which capacity
they have received consulting fees. SG is a member of the scientific advisory
board, DSMB, and an investigator with Affiris, Astellas, Astra-Zeneca, BMS,
Elan, Epix, ExonHit, GE Health Care, Janssen-Cilag, Lundbeck, Lilly, Merz,
Myriad, Neurochem, Novartis, Pfizer, Sanofi-Aventis, Schering-Plough, Servier,
Sonexa, UBC, and Wyeth. In the past 5 years, VAH has received honoraria
from Bayer Healthcare, Eisai, Janssen, Lilly, Novartis, Pfizer, Servier, and Wyeth.
RI has received consultant fees from APK, Austroplant, BDI, Beltz Test, BOD,
Caritas Siegen, Double Helix Development, Eisai, Friedrichverlag, GE
Healthcare, Hogrefe, IFE, Janssen, KDA, Landesinitiative Demenz Service NRW,
LVR Düren, Medical Tribune, Med. Komm., Novartis, Pfizer, Pfrimmer Nutritia,
Pierrel, Schwabe, Thieme, Urban & Vogel, Westermayer. PR has received
honoraria or royalties from Eisai, Wyeth, Novartis, Janssen, and GE Healthcare.
Received: 13 May 2011 Revised: 6 July 2011
Accepted: 14 September 2011 Published: 14 September 2011
References
1. Robert P, Ferris P, Gauthier S, Ihl R, Winblad B, Tennigkeit F: Review of
Alzheimer’s disease scales: is there a need for a new multi-domain scale
for therapy evaluation in medical practice? Alzheimer’s Res Ther 2010, 2:24.
2. Reisberg B, Ferris SH, Leon MJ, Crook T: The global deterioration scale for
assessment of primary degenerative dementia. Am J Psychiatr 1982,
139:1136-1139.
3. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale
for the staging of dementia. Br J Psychiatry 1982, 140:566-572.
4. Reisberg B: Functional assessment staging (FAST). Psychopharmacol Bull
1988, 24:653-659.
5. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: a practical
method for grading the cognitive state of patients for the clinician. J
Psychiatr Res 1975, 12:189-198.
6. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s disease.
Am J Psychiatr 1984, 141:1356-1364.
7. Saxton J, Swihart AA: Neuropsychological assessment of the severely
impaired elderly patient. Clin Geriatr Med 1989, 5:531-543.
8. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA,
Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment
of psychopathology in dementia. Neurology 1994, 44:2308-2314.
9. Gélinas I, Gauthier L, McIntyre M, Gauthier S: Development of a functional
measure for persons with Alzheimer’s disease: the disability assessment
for dementia. Am J Occup Ther 1999, 53:471-481.
10. Bland JM, Altman DG: Cronbach’s alpha. Br Med J 1997, 314:572.
11. Guyatt G, Walter S, Norman G: Measuring change over time: assessing the
usefulness of evaluative instruments. J Chron Dis 1987, 40:171-178.
12. Cohen J: Statistical Power Analysis for the Behavioral Sciences. 2 edition.
Hillsdale, NJ: Laurence Erlbaum Associates; 1988.
13. Rockwood K, Gauthier S: Trial Design and Outcomes in Dementia Therapeutic
Research London: Taylor & Francis Group; 2006.
14. Guidelines on Medicinal Products for the Treatment of Alzheimer’s
Disease and Other Dementias: European Medicines Agency. [http://www.
emea.europa.eu].
15. Black R, Greenberg B, Ryan JM, Posner H, Seeburger J, Amatniek J,
Resnick M, Mohs R, Miller DS, Saumier D, Carrillo MC, Stern Y: Scales as
outcome measures for Alzheimer’s disease. Alzheimer’s & Dementia 2009,
5:324-339.
16. Vogel A, Bhattacharya S, Waldorff FB, Waldemar G: Proxy-rated quality of
life in Alzheimer’s disease: a three-year longitudinal study. Int
Psychogeriatr 2011, 28:1-8.
17. Thomas SJ, Grossberg GT: Memantine: a review of studies into its safety
and efficacy in treating Alzheimer’s disease and other dementias. Clin
Interv Aging 2009, 4:367-377.
doi:10.1186/alzrt89
Cite this article as: Holthoff et al.: Validation of the relevant outcome
scale for Alzheimer’s disease: a novel multidomain assessment for daily
medical practice. Alzheimer’s Research & Therapy 2011 3:27.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Holthoff et al. Alzheimer’s Research & Therapy 2011, 3:27
http://alzres.com/content/3/5/27
Page 10 of 10